Skip to content

A study on Intestinal Disease and Lifestyle - Disease characteristics and lifestyle factors in inflammatory bowel disease and irritable bowel syndrome

A study on Intestinal Disease and Lifestyle - Disease characteristics and lifestyle factors in inflammatory bowel disease and irritable bowel syndrome - IDeaL study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON29893
Enrollment
1500
Registered
2006-04-19
Start date
2006-05-01
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic intestinal inflammation inflammatory bowel disease

Interventions

None listed

Sponsors

Wageningen Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patients with Crohn's disease, ulcerative colitis, and/or irritable bowel syndrome. 2. Patients who visited a gastroenterologist at Gelderse Vallei Hospital in the last 10 years. 3. Patients aged 18 years and older.

Exclusion criteria

Exclusion criteria: IBD and IBD patients who moved to a foreign country or when no address is available.

Design outcomes

Primary

MeasureTime frame
- Disease characteristics; date of first complaints and diagnosis, date of last complaints due to IBD and/or IBS and type of complaints, frequency of complaints, and occurrence of extra-intestinal manifestations. - Lifestyle characteristics; dietary intake, smoking behaviour, alcohol use, stress, depression, anxiety, physical and sexual abuse.

Secondary

MeasureTime frame
- Clinical characteristics; measles vaccination or (perinatal) infection, gastroenteritis, appendectomy, cholestectomy, hysterectomy, use of antibiotics, and use of oral contraceptive and hormone replacement therapy (for women only), family members with UC, CD, or IBS. - Treatment characteristics; number of hospitalizations due to IBD or IBS, number and kind of operations due to IBD, medication use including analgesic, and Prednisone and Prednisolon.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)